NDC 58468-0225

Cablivi

Caplacizumab

Cablivi is a Intravenous;subcutaneous Kit in the Human Prescription Drug category. It is labeled and distributed by Genzyme Corporation. The primary component is .

• Product ID: 58468-0225_0e57be04-a804-4a12-ad74-90947fc677a5
• NDC: 58468-0225
• Product Type: Human Prescription Drug
• Proprietary Name: Cablivi
• Generic Name: Caplacizumab
• Dosage Form: Kit
• Route of Administration: INTRAVENOUS;SUBCUTANEOUS
• Marketing Start Date: 2019-02-06
• Marketing Category: BLA / BLA
• Application Number: BLA761112
• Labeler Name: Genzyme Corporation
• Active Ingredient Strength: 0
• NDC Exclude Flag: N
• Listing Certified Through: 2022-12-31

Packaging

NDC 58468-0225-1

1 KIT in 1 CARTON (58468-0225-1) * 1 mL in 1 VIAL, GLASS (58468-0227-1) * 1 mL in 1 SYRINGE, GLASS (58468-0229-1)

• Marketing Start Date: 2019-02-06
• NDC Exclude Flag: N
• Sample Package?: N

NDC SPL Data Element Entries

NDC 58468-0225-1 [58468022501]

Cablivi KIT

• Marketing Category: BLA
• Application Number: BLA761112
• Product Type: HUMAN PRESCRIPTION DRUG
• Billing Unit: EA
• Marketing Start Date: 2019-02-06

Drug Details

OpenFDA Data

• SPL SET ID: 2348f06e-8004-4040-832e-e9e86a39f905
• Manufacturer:
  • Genzyme Corporation
• RxNorm Concept Unique ID - RxCUI:
  • 2110618
  • 2110616